SDC2+ Exosome Compositions for Immune Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases such as diabetes and inflammatory conditions lack effective methods to modulate immune responses and reduce inflammation, particularly in targeting specific tissues like the brain and joints, where existing therapies may not adequately address the underlying immune dysregulation.
Innovation Solution
Development of exosome compositions enriched with SDC2+ exosomes, which are derived from mesenchymal stem cells and have immunosuppressive properties, for use in treating diabetes and modulating inflammation by delivering them via various routes, including intravenous and topical applications, to exert paracrine signaling and reduce immune response activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for diabetes and inflammatory conditions, then treatment simplicity is maintained, but effectiveness in modulating immune responses and reducing inflammation is insufficient
Solution Approach 1:
The patent extracts and isolates exosomes from mesenchymal stem cells, separating the therapeutic active components from the whole cell system. This allows the immunomodulatory properties to be delivered without the complexity of cell transplantation, achieving effective immune response modulation through purified exosome compositions.
Solution Approach 2:
Exosomes serve as intermediary carriers that transfer immunomodulatory signals and molecules between cells. They mediate the therapeutic effect by delivering bioactive molecules to target tissues, enabling effective immune response modulation without direct cell-to-cell contact or complex cellular interactions.
2Reliability
If existing therapies are applied to target specific tissues like the brain and joints, then tissue-specific treatment is attempted, but adequate addressing of underlying immune dysregulation is not achieved
Solution Approach 1:
The exosome compositions possess multi-functional immunomodulatory capabilities that can address immune dysregulation across different tissue contexts. The same exosome formulation can be applied to various conditions (diabetes, inflammatory diseases, neurological disorders) by targeting different delivery routes, achieving universal immune modulation without requiring complex tissue-specific modifications.
Solution Approach 2:
The patent modifies parameters of the exosome compositions including surface protein expression (SDC2 enrichment), cargo loading, and delivery parameters to optimize immunomodulatory effects. By changing these parameters, the exosomes achieve effective immune dysregulation addressing across different tissue targets while maintaining ease of administration.
3Reliability
If mesenchymal stem cells are used directly for therapy, then immunosuppressive properties are achieved, but cell-related complications and delivery challenges arise
Solution Approach 1:
The patent extracts the immunosuppressive functional components (exosomes) from mesenchymal stem cells, isolating the therapeutic activity from the cellular vehicle. This eliminates cell-related complications such as immunogenicity, engraftment issues, and ethical concerns while preserving the immunosuppressive properties through exosome-mediated delivery.
Solution Approach 2:
Exosomes serve as simplified copies or surrogates of the whole mesenchymal stem cell system, carrying the essential immunomodulatory signals and molecules. They replicate the beneficial immunosuppressive functions without the complexity and risks associated with live cell therapy, providing a more controllable and scalable therapeutic platform.
Data Source
AI summary
Disclosed herein are compositions comprising isolated exosomes, for instance exosomes wherein at least 20% of the exosomes comprise SDC2, methods of isolation, and methods of use.